Gilead Sciences, Inc. (NASDAQ:GILD) Shareholders to Collect $0.82 Quarterly Dividend

Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend on Thursday, October 29th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share by the biopharmaceutical company on Wednesday, December 30th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th.

Gilead Sciences has a dividend payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Gilead Sciences to earn $9.94 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.0%.

Gilead Sciences Stock Up 4.0%

Gilead Sciences stock opened at $165.61 on Friday. Gilead Sciences has a 1-year low of $114.02 and a 1-year high of $165.70. The stock has a market cap of $205.35 billion, a PE ratio of -62.03 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock’s fifty day moving average is $150.33 and its two-hundred day moving average is $139.55.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Friday, October 30th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company’s revenue was up 6.8% on a year-over-year basis. During the same period last year, the firm posted $2.47 EPS. On average, sell-side analysts expect that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.